Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025
Globenewswire·2025-07-21 12:14
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the most difficul ...